SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) June 10, 1999
SCIOS INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-11749 95-3701481
(State of Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
2450 Bayshore Parkway, Mountain View, California 94043
(Address of Principal Executive Offices)
Registrant's telephone number, including area code (650) 966-1550
Item 5. Other Events
On June 9, 1999, Scios Inc. announced that the May 11, 1998 commercial
alliance with Bayer Corporation regarding Natrecor(R) (nesiritide) was
terminated.
Exhibits.
99.1 Press Release dated June 9, 1999
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf of the
undersigned, thereunto duly authorized.
SCIOS INC.
Date: June 10, 1999 By:
David S. Gryska
Chief Financial Officer
INDEX TO EXHIBITS
SCIOS INC.
Report on Form 8-K dated June 10, 1999
Exhibit Description Method of Filing
99.1 Press Release dated June 9, 1999 Filed electronically herewith
Exhibit 99.1
SCIOS AND BAYER DISSOLVE COMMERCIAL ALLIANCE REGARDING NATRECOR(R) IN
ACUTE CONGESTIVE HEART FAILURE
- -Scios designing new clinical trial while reviewing new partner opportunities-
MOUNTAIN VIEW, Calif. - June 9, 1999 - Scios Inc. (NASDAQ: SCIO) today announced
that the commercial alliance with Bayer Corporation, formed in May 1998
regarding Natrecor(R) (nesiritide) in acute congestive heart failure, has been
dissolved. Scios recently received notice from the Food and Drug Administration
(FDA) that Natrecor would need to successfully complete additional clinical
study to gain approval.
"Bayer decided to reassess the basis of its continued commercial alliance with
Scios regarding Natrecor after the FDA non-approvable letter on the Natrecor
new drug application," said Richard B. Brewer, President and CEO of Scios Inc.
"Agreement could not be reached on a new commercial alliance."
With the dissolution of the alliance with Bayer Corporation, all rights and
responsibilities for Natrecor development and commercialization revert to Scios.
As a result the company is reviewing new partner opportunities. The company is
now directing its full attention to designing an additional clinical trial to
meet the FDA's concerns expressed in the April, 1999 Natrecor non-approvable
letter. Scios is collaborating with outside experts in the congestive heart
failure community in the design of the next clinical study. In addition, Scios
will work in close collaboration with the FDA. The full details of the trial
will probably not be available until mid-summer (i.e. trial enrollment size,
length of study, and cost).
Scios Inc.
Scios is a biopharmaceutical company engaged in the discovery, development,
manufacture and commercialization of novel human therapeutics. Scios has
research and development collaborations with Wyeth-Ayerst Laboratories, the
pharmaceutical division of American Home Products Corporation, Kaken
Pharmaceutical Co., Ltd., Eli Lilly and Company, The DuPont Pharmaceuticals
Company and Novo Nordisk A/S of Denmark. Scios' commercial operations division
successfully markets six psychiatric products. Additional information on Scios
is available at its web site located at http://www.sciosinc.com and in the
Company's various fillings with the Securities and Exchange Commission.
The statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties, and may include
references to the continued development and commercialization of Natrecor, as
well as other risks detailed from time to time in the reports filed by Scios
with the SEC, including annual reports on Form 10K for the year ended December
31, 1998 and subsequent reports on Form 10Q.
# # #
